STOCK TITAN
  1. Home
  2. Sec-filings
  3. LVTX
  4. [Form 4] LAVA Therapeutics NV Insider Trading Activity

[Form 4] LAVA Therapeutics NV Insider Trading Activity

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

LAVA Therapeutics (LVTX): insider sales reported by Gilde Healthcare affiliates. The reporting persons disclosed open‑market sales of common shares on multiple dates. On 10/16/2025, they sold 690,239 shares at a weighted average price of $1.49, with 4,128,912 shares beneficially owned afterward. On 10/17/2025, they sold 1,181,131 shares at a weighted average price of $1.47, with 2,947,781 shares beneficially owned afterward. On 10/20/2015, they sold 1,000,000 shares at a weighted average price of $1.46, leaving 1,947,781 shares beneficially owned.

The prices reflect weighted averages across trade ranges disclosed for each date, and the shares are held directly by Cooperatieve Gilde Healthcare IV U.A., with related entities noted; each related entity disclaims beneficial ownership except to the extent of its pecuniary interest.

Positive

  • None.

Negative

  • None.

Insights

Significant open-market insider sales reduced a key holder’s stake; no derivatives reported.

The filing discloses three open‑market sales of **LAVA Therapeutics NV (LVTX)** common shares by a reporting group. Reported sales were 690,239 shares at a weighted average of $1.49 on 10/16/2025, 1,181,131 shares at a weighted average of $1.47 on 10/17/2025, and 1,000,000 shares at a weighted average of $1.46 on 10/20/2015. After these transactions, reported beneficial ownership stands at **1,947,781** shares, held directly by **Cooperatieve Gilde Healthcare IV U.A.**

The filing indicates it was submitted by more than one reporting person, and states that **Gilde Healthcare IV Management B.V.** and **Gilde Healthcare Holding B.V.** disclaim beneficial ownership beyond their pecuniary interests. The sales are coded "S" (open‑market or private sale) and include detailed weighted‑average price ranges, with an undertaking to provide trade‑level detail upon request. No derivative securities are reported in Table II.

Items to watch: subsequent Forms 4 for additional dispositions, any changes in reported beneficial ownership, and whether further transactions occur after 10/17/2025. The weighted‑average price ranges disclosed ($1.44–$1.53) frame recent execution levels for these transactions.

Insider Cooperatieve Gilde Healthcare IV U.A., Gilde Healthcare Holding B.V.
Role 10% Owner | 10% Owner
Sold 2,871,370 shs ($4.22M)
Type Security Shares Price Value
Sale Common Shares 1,181,131 $1.47 $1.74M
Sale Common Shares 690,239 $1.49 $1.03M
Sale Common Shares 1,000,000 $1.46 $1.46M
Holdings After Transaction: Common Shares — 2,947,781 shares (Direct)
Footnotes (1)
  1. This figure is the weighted average sales price of multiple trades ranging from $1.47 to $1.53 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, LAVA Therapeutics NV or any security holder of LAVA Therapeutics NV full information about the number of shares sold at each separate price upon request. The shares are held directly by Cooperatieve Gilde Healthcare IV U.A. ("Gilde Healthcare"). Gilde Healthcare IV Management BV ("GHCIVM") manages and advises Gilde Healthcare and is owned by Gilde Healthcare Holding BV ("GHH"). Each of GHCIVM and GHH disclaims beneficial ownership of the shares held by Gilde Healthcare, except to the extent of its respective pecuniary interests therein. This figure is the weighted average sales price of multiple trades ranging from $1.44 to $1.52 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, LAVA Therapeutics NV or any security holder of LAVA Therapeutics NV full information about the number of shares sold at each separate price upon request. This figure is the weighted average sales price of multiple trades ranging from $1.44 to $1.51 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, LAVA Therapeutics NV or any security holder of LAVA Therapeutics NV full information about the number of shares sold at each separate price upon request.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cooperatieve Gilde Healthcare IV U.A.
(Last) (First) (Middle)
STADSPLATEAU 36
(Street)
UTRECHT P7 3521 AZ
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
LAVA Therapeutics NV [ LVTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 10/16/2025 S 690,239 D $1.49(1) 4,128,912 D(2)
Common Shares 10/17/2025 S 1,181,131 D $1.47(3) 2,947,781 D(2)
Common Shares 10/20/2015 S 1,000,000 D $1.46(4) 1,947,781 D(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Cooperatieve Gilde Healthcare IV U.A.
(Last) (First) (Middle)
STADSPLATEAU 36
(Street)
UTRECHT P7 3521 AZ
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Gilde Healthcare Holding B.V.
(Last) (First) (Middle)
STADSPLATEAU 36
(Street)
UTRECHT P7 3521 AZ
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. This figure is the weighted average sales price of multiple trades ranging from $1.47 to $1.53 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, LAVA Therapeutics NV or any security holder of LAVA Therapeutics NV full information about the number of shares sold at each separate price upon request.
2. The shares are held directly by Cooperatieve Gilde Healthcare IV U.A. ("Gilde Healthcare"). Gilde Healthcare IV Management BV ("GHCIVM") manages and advises Gilde Healthcare and is owned by Gilde Healthcare Holding BV ("GHH"). Each of GHCIVM and GHH disclaims beneficial ownership of the shares held by Gilde Healthcare, except to the extent of its respective pecuniary interests therein.
3. This figure is the weighted average sales price of multiple trades ranging from $1.44 to $1.52 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, LAVA Therapeutics NV or any security holder of LAVA Therapeutics NV full information about the number of shares sold at each separate price upon request.
4. This figure is the weighted average sales price of multiple trades ranging from $1.44 to $1.51 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, LAVA Therapeutics NV or any security holder of LAVA Therapeutics NV full information about the number of shares sold at each separate price upon request.
Cooperatieve Gilde Healthcare IV U.A., By: /s/ Edwin de Graaf, Managing Director 10/20/2025
Gilde Healthcare IV Management B.V., By: /s/ Edwin de Graaf, Managing Director 10/20/2025
Gilde Healthcare Holding B.V., By: /s/ Edwin de Graaf, Managing Director 10/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR